Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

---

Sehn L. H., Herrera A. F., Flowers C. R., Kamdar M. K., McMillan A., Hertzberg M., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.38, sa.2, ss.155-176, 2020 (SCI-Expanded, Scopus)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 38 Sayı: 2
• Basım Tarihi: 2020
• Doi Numarası: 10.1200/jco.19.00172
• Dergi Adı: JOURNAL OF CLINICAL ONCOLOGY
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, CAB Abstracts, CINAHL, EMBASE, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
• Sayfa Sayıları: ss.155-176
• Ankara Üniversitesi Adresli: Evet

Özet

PURPOSE Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly, with limited treatment options. The antibody-drug conjugate polatuzumab vedotin targets CD79b, a B-cell receptor component.